Alta Stays Flexible with New $500 Million Fund
This article was originally published in Start Up
Executive Summary
Now, Alta Partners is shifting direction. Rather than raise a fourth early-stage biopharma fund, Alta opted to raise a single $500 million fund, Alta Partners VIII, which it will commit to biopharmaceutical and medical device companies of all stages.
You may also be interested in...
Diversification vs. Sector Focus: Longitude, Enterprise Seek Latitude in Life Sciences
The age of specialization is not over for venture capital firms. The health care team from Pequot Ventures left the hedge-fund heavy firm to start Longitude Capital. Meanwhile, Enterprise Partners Venture Capital is said to be raising a health care only fund.
Diversification vs. Sector Focus: Longitude, Enterprise Seek Latitude in Life Sciences
The age of specialization is not over for venture capital firms. The health care team from Pequot Ventures left the hedge-fund heavy firm to start Longitude Capital. Meanwhile, Enterprise Partners Venture Capital is said to be raising a health care only fund.
The Lure of Late-Stage Device Investing
In 2006, the number of late-stage private equity deals in the medical device sector is up significantly from 2005. At the IN3 East medtech conference in October, a lively panel of venture capital investors from Galen Partners, 3i, Matignon Technologies and OrbiMed Advisors discussed why this is so, and the risks, benefits and models for late-stage investing.